Reckitt Launched Mucinex Cold and Fever Treatment

The FDA-approved 12-hour medication rolled out across the U.S. to bolster supplies for the upcoming respiratory season.

Updated on Sept. 22, 2026 in Consumer Goods

Close-up of a sterile industrial conveyor belt in a pharmaceutical factory with rows of empty capsules moving along a metallic track. — Reckitt has launched its new Mucinex 12HR Cold & Fever medication in the U.S. and expanded its North Carolina manufacturing facility to bolster supply chain resilience. AI Illustration. Upload story photo >

Live Poll

Is now a good time to stock up on cold and flu medication for your household?

In August 2026, Reckitt launched its new Mucinex 12HR Cold & Fever Multi-Symptom medication across the United States following FDA approval. The new formulation aims to meet consumer demand during the peak respiratory illness season.

Why it matters

The product launch and the expansion of Reckitt’s manufacturing facility in North Carolina are designed to improve supply resilience amid rising seasonal illness activity. Increased domestic capacity helps the company manage inventory pressures and shifting global freight costs.

The new Mucinex 12HR formulation utilizes a combination of guaifenesin, dextromethorphan HBr, and naproxen sodium. Market assessments from August 2026 indicated a firmer guaifenesin market than in July 2026.

The players

Reckitt

Reckitt is a multinational consumer goods company that produces health, hygiene, and nutrition products.

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs.

The details

Reckitt expanded its Mucinex portfolio to include this multi-symptom option, which provides 12-hour relief for patients. To support this growth, the company is increasing domestic manufacturing capacity at its North Carolina plant, helping to mitigate the impact of higher freight costs from India.

August 2026: FDA approval and launch of Mucinex 12HR Cold & Fever.
October 2026 through April 2027: Typical window for rising influenza activity.
Q4 2026: Anticipated peak for seasonal guaifenesin procurement.
December 2026 through February 2027: Typical peak period for respiratory illness.

Market Landscape

The expansion follows the pattern set by the 2026 seasonal respiratory inventory procurement cycles to ensure product availability during high-demand months. Reckitt is scaling domestic production to navigate volatile global supply chains and rising transportation expenses.

Consumers can expect the new Mucinex 12HR formulation to be available on pharmacy shelves nationwide as they prepare for the fall and winter sickness season. This expansion aims to ensure reliable product access for families managing multi-symptom cold and fever concerns.

The takeaway

As respiratory illness activity typically increases during winter months, maintaining personal inventory of necessary medications can prevent last-minute shopping disruptions. Shoppers should check product labels carefully for the specific symptom coverage provided by this new 12-hour formulation.